PDCD1 and nasopharyngeal carcinoma: Our data also suggest potential immunotherapeutic targets that may be used in combination with PD-1/PD-L1 blockade to further improve response rates in NPC.61,62 LAG-3 and HAVCR2, which have rarely been studied in NPC to date, were highlighted as the most prominent immune checkpoint molecules in CD8+ Tdysfunctional in NPC.